Neurodegenerative Disorders Drug Development Pipeline Review 2017: Over 1,400 Products in Active Development in the Neurodegenerative Disorders Therapy Area - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Neurodegenerative Disorders Drug Development Pipeline Review, 2017" report to their offering.

Neurodegenerative disorders are a cluster of conditions that affect the central nervous system. They include both hereditary and sporadic conditions that are characterized by slow, irreversible, progressive dysfunction of the nervous system with the increasing degeneration of neurons, which causes symptoms such as motor impairment, memory loss and declining cognitive ability. Neurodegenerative disorders cannot currently be cured, and treatment is aimed at managing the disease indication in order to reduce the severity of symptoms and slow progression.

There are over 1,400 products in active development in the neurodegenerative disorders therapy area. The current market landscape consists of a number of biologics and small molecules, while the pipeline also consists of gene therapies and cell therapies, demonstrating broader pharmaceutical research and development.

Small molecule drugs dominate the pipeline, with approximately 64% of total pipeline molecules. In comparison, the number of biologics in the pipeline is much lower, representing approximately 26% of the pipeline. Overall the neurodegenerative disorders pipeline is large, with a substantial proportion of products being early-stage assets at the Preclinical development stage.

Companies Mentioned

  • AB Science SA
  • AC Immune SA
  • AFFiRiS AG
  • ALSP Inc.
  • AbbVie Inc
  • Accera Inc.
  • Acelot Inc.
  • Actinogen Limited
  • Acumen Pharmaceuticals Inc.
  • Addex Therapeutics Ltd
  • Affibody AB
  • Alector LLC
  • Alkermes Plc
  • Allergan Plc
  • Allinky Biopharma
  • AlzProtect SAS
  • Alzhyme Pty Ltd
  • Alzinova AB
  • Amarantus Bioscience Holdings Inc.
  • Amgen Inc.
  • (100+ Others)

Key Topics Covered:

1. Research Report Guidance

2. Executive Summary

3. Introduction

4. Neurodegenerative Disorders Report Coverage

5. Therapeutics Development

6. Therapeutics under Development by Companies

7. Therapeutics under Investigation by Universities/Institutes

8. Pipeline Products Glance

9. Products under Development by Companies

10. Products under Investigation by Universities/Institutes

11. Companies Involved in Therapeutics Development

12. Therapeutics Assessment

13. Dormant Projects

14. Discontinued Products

15. Product Development Milestones

16. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/3vdcsm/neurodegenerative

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Drug Discovery

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Drug Discovery